Cardiovascular trials and diabetes treatments: A regulatory maze

Diabetes and Vascular Disease Research

Volumn 9, Issue 2, 2012, Pages 83-84

  Matthews, David R ^a,b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INCRETIN; INSULIN;

ASPIRATION PNEUMONIA; CARDIOVASCULAR RISK; DRUG INDUSTRY; EDITORIAL; FOOD AND DRUG ADMINISTRATION; HEALTH CARE COST; HEALTH SERVICE; HEART FAILURE; HUMAN; HYPOGLYCEMIA; KIDNEY FAILURE; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PERIPHERAL VASCULAR DISEASE; STOMACH BYPASS;

CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; COMORBIDITY; DIABETES MELLITUS, TYPE 2; DRUG APPROVAL; EVIDENCE-BASED MEDICINE; HUMANS; HYPOGLYCEMIC AGENTS; PATIENT SAFETY; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84861031909     PISSN: 14791641     EISSN: 17528984     Source Type: Journal    
DOI: 10.1177/1479164112441380     Document Type: Editorial

References (9)

1. Yusta B, Baggio LL, Estall JL, Koehler JA, Holland DP, Li H, et al. GLP-1 receptor activation improves beta cell function and survival following induction of endoplasmic reticulum stress. Cell Metab 2006; 4: 391-406. (Pubitemid 44752565)
2. Drucker DJ, Lovshin J, Baggio L, Nian M, Adatia F, Boushey RP, et al. New developments in the biology of the glucagon-like peptidesGLP-1 and GLP-2. Ann N Y Acad Sci 2000; 921: 226-232. (Pubitemid 32094547)
3. Ashrafian H, Athanasiou T, Li JV, Bueter M, Ahmed K, Nagpal K, et al. Diabetes resolution and hyperinsulinaemia after metabolic Roux-en-Y gastric bypass. Obes Rev 2011; 12 (5) :e257-e272.
4. FDA. Guidance for industry: diabetes mellitus - evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes, 2008, available at: http://www.fda.gov/cder/guidance/index.htm.
5. Jonasson JM, Ljung R, Talback M, Haglund B, Gudbjornsdottir S and Steineck G. Insulin glargine use and short-term incidence of malignancies-a population-based follow- up study in Sweden. Diabetologia 2009; 52: 1745-1754.
6. Gerstein HC, Miller ME, Byington RP, Goff DC, Jr, Bigger JT, Buse JB, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-2559. (Pubitemid 351831356)
7. Drug policy and strategy analyses to inform R&D and strategic planning decisions. Tufts Center for the Study of Drug Development, 2011, available at: http://csdd.tufts.edu/research/research-milestones.
8. Stimplete Elixir. Pharmaceutical Journal 1960; March.
9. Arnold M. New Poems, 1867.